Join our daily newsletter At The Bell to receive exclusive market insights
- The first patient in Race Oncology’s (RAC) Phase 1b/2 acute myeloid leukaemia (AML) trial in Israel has been dosed with a novel treatment
- The trial is assessing the efficacy of RAC’s drug Zantrene in combination with two other drugs in patients with relapsed or refractory AML
- Race Oncology is also conducting a separate Phase 2 trial of Zantrene in patients with intramedullary AML in Australia
- Shares are trading flat at $3.39 at 11:44 am AEST
The first patient in Race Oncology’s (RAC) Phase 1b/2 acute myeloid leukaemia (AML) trial in Israel has been dosed with a novel treatment.
The trial at the Chaim Sheba Medical Center is being led by Professor Arnon Nagler who conducted the Phase 2 single agent Zantrene trial in relapsed and refectory AML patients.
The study is assessing the efficacy of Race Oncology’s cancer drug Zantrene (bisantrene dihydrochloride) in combination with fludarabine and clofarabine to treat patients with relapsed or refractory AML.
Race Chief Medical Officer David Fuller said the company was delighted to see the clinical project under way.
“This study is also an important step in our journey towards approval of Zantrene in this area of high unmet medical need,” he said.
Phase 1b will be a dose-escalation stage and will assess for any dose-limiting toxicities. Phase 2 will enrol up to 17 patients and evaluate the efficacy of the novel combination treatment at the dose determined in the previous stage.
The trial is expected to take between 36 and 40 months to complete. Over this time Race Oncology will pay Chaim Sheba a total fee of US$668,739 (A$910,500) at various milestones.
Race Oncology is also conducting a separate Phase 2 trial of Zantrene in patients with intramedullary AML in Australia.
Shares were trading flat at $3.39 at 11:44 am AEST.
